The growth of highly sought-after weight-loss drugs like Wegovy and Ozempic, otherwise known as GLP-1 medications, represents ...

A study has identified the key role of lateral septum neurons in the effects of the anti-obesity drug liraglutide, offering ...

Novo Nordisk became the biggest European company, as measured by market value, earlier this week, so investors are starting to catch on. "We see anti-obesity drugs as one of the biggest drug classes ...

Wegovy, Zepbound and similar medications all lead to metabolic improvements, but scientists are starting to unpick the ...

Anti-obesity medications (AOMs) such as GLP-1s will play an unquestionable long-term role in balancing the “food trilemma”.

The market for obesity treatment is expected to expand more than fifteenfold by 2030 due to escalating competition, fueled by ...

Biden issued the statement in response to news that Eli Lilly will offer a direct-to-consumer version of its anti-obesity drug Zepbound for $399 for a month's supply, down from a typical list price of ...

Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allowing rival ...

Semaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those ...

is releasing a single-dose version of its weight loss drug Zepbound for patients who don't have insurance coverage. The ...

The North Chicago drugmaker could have a new foe — or frenemy — in a fellow Big Pharma firm trying to find wider uses for its ...

A total of 77 suicide deaths in GLP-1 agonist users and 71 in SGLT2 inhibitor users were identified. Subgroup analyses ...